Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialAxel Hauschild, Paul B. Chapman, Jean‐Jacques Grob et al.|The Lancet|2012Cited by 3k
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in MelanomaCatherine S. Grasso, Antoni Ribas, Petra Ross‐Macdonald et al.|Cancer Cell|2020Cited by 379